Name | FIDAS-5 |
---|---|
Synonyms | MFCD32671894 |
Description | FIDAS-5 is a potent and orally active methionine S-adenosyltransferase 2A (MAT2A) inhibitor with an IC50 of 2.1 μM. FIDAS-5 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding. FIDAS-5 has anticancer activities[1]. |
---|---|
Related Catalog | |
Target |
IC50: 2.1 μM (Methionine S-adenosyltransferase 2A (MAT2A))[1] |
In Vitro | FIDAS-5 (3 μM; 7 days; LS174T cells) treatment significantly inhibits the proliferation of LS174T cells[1]. FIDAS-5 (3 μM) treatment inhibits the expression of c-Myc and cyclinD1 in LS174T CRC cells. And FIDAS-5 induces the expression of cell cycle inhibitor, p21WAF1/CIP1[1]. FIDAS-5 (3 μM; 36 h) treatment reduces the levels of both S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) in LS174T cells[1]. Cell Viability Assay[1] Cell Line: LS174T colorectal cancer (CRC) cells Concentration: 3 μM Incubation Time: 7 days Result: Significantly inhibited the proliferation of LS174T cells. |
In Vivo | FIDAS-5 (20 mg/kg; oral gavage; daily; for two weeks; athymic nude mice) treatment significantly inhibits the growth of xenograft tumors, with minimal difference in body weight[1]. Mice are treated with FIDAS-5 (20 mg/kg) for 1 week. The liver SAM levels are significantly reduced[1]. Animal Model: 16 athymic nude mice injected with HT29 CRC cells[1] Dosage: 20 mg/kg Administration: Oral gavage; daily; for two weeks Result: Significantly inhibited the growth of xenograft tumors. |
References |
Molecular Formula | C15H13ClFN |
---|---|
Molecular Weight | 261.72 |